You might also like
Stryker Corporation is a global leader in medical technologies, providing innovative products and services aimed at enhancing patient and healthcare outcomes . The company operates through two main business segments: MedSurg and Neurotechnology, and Orthopaedics and Spine . Stryker's offerings include a wide range of medical instruments, endoscopic devices, and orthopedic solutions .
-
MedSurg and Neurotechnology - Offers a diverse range of products including Instruments, Endoscopy, Medical, Neurovascular, and Neuro Cranial solutions, contributing significantly to the company's revenue .
- Instruments - Provides surgical tools and equipment for various medical procedures .
- Endoscopy - Develops advanced endoscopic devices for minimally invasive surgeries .
- Medical - Supplies a variety of medical devices and equipment for healthcare facilities .
- Neurovascular - Specializes in products for the treatment of neurovascular conditions .
- Neuro Cranial - Focuses on solutions for cranial surgeries and treatments .
-
Orthopaedics and Spine - Delivers comprehensive orthopedic and spine solutions, including Knees, Hips, Trauma and Extremities, Spine, and Other products .
- Trauma and Extremities - Provides implants and devices for trauma care and extremity surgeries .
- Knees - Offers knee replacement and repair solutions .
- Spine - Develops products for spinal surgeries and treatments .
- Hips - Supplies hip replacement and repair solutions .
- Other - Includes various additional orthopedic products .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Kevin A. Lobo ExecutiveBoard | Chair, Chief Executive Officer, and President | Director, Parker-Hannifin Corporation; Director, AdvaMed; Chair, Valley Health System Board of Trustees | Kevin A. Lobo has been CEO since 2012 and Chair since 2014. He previously held leadership roles at Johnson & Johnson. | View Report → |
Glenn S. Boehnlein Executive | Vice President, Chief Financial Officer (until April 1, 2025) | None | Glenn S. Boehnlein has been CFO since 2016. He will transition to Advisor to the CEO on April 1, 2025. | |
J. Andrew Pierce Executive | Group President, MedSurg and Neurotechnology | None | J. Andrew Pierce has been Group President since 2021, leading the MedSurg and Neurotechnology divisions. | |
M. Kathryn Fink Executive | Vice President, Chief Human Resources Officer | None | M. Kathryn Fink has been Chief Human Resources Officer since 2016. | |
Preston Wells Executive | Vice President, Chief Financial Officer (effective April 1, 2025) | None | Preston Wells has held multiple finance leadership roles at Stryker, including VP, Investor Relations, and Group CFO for Orthopaedics. | |
Robert S. Fletcher Executive | Vice President, Chief Legal Officer | None | Robert S. Fletcher joined Stryker in 2019 after serving as Worldwide VP, Litigation at Johnson & Johnson. | |
Spencer S. Stiles Executive | Group President, Orthopaedics | None | Spencer S. Stiles has been Group President since 2021, previously overseeing Orthopaedics and Spine. | |
Viju S. Menon Executive | Group President, Global Quality and Operations | None | Viju S. Menon joined Stryker in 2018 and oversees global quality and operations. He previously held senior supply chain roles at Verizon. | |
William E. Berry Jr. Executive | Vice President, Chief Accounting Officer | None | William E. Berry Jr. joined Stryker in 2011 and has been Chief Accounting Officer since 2021. | |
Yin C. Becker Executive | Vice President, Chief Corporate Affairs Officer | None | Yin C. Becker has been Chief Corporate Affairs Officer since 2016, leading communications and public affairs strategies. | |
Allan C. Golston Board | Director (retiring May 8, 2025) | President, U.S. Program for the Bill and Melinda Gates Foundation; Director, Harley-Davidson | Allan C. Golston has been a director since 2011 and is retiring in May 2025. | |
Andrew K. Silvernail Board | Director | Director, Boys & Girls Club of Lake County | Andrew K. Silvernail has been a director since 2013 and is the former CEO of IDEX Corporation. | |
Giovanni Caforio, M.D. Board | Director | Chairman, Bristol-Myers Squibb; Director, PhRMA; Member, Business Roundtable; Member, CEO Roundtable on Cancer | Giovanni Caforio, M.D., has been a director since 2020 and is the Chairman of Bristol-Myers Squibb. | |
Lisa M. Skeete Tatum Board | Director | Founder and CEO, Landit, Inc.; Director, Union Square Hospitality Group; Director, World 50, Inc.; Trustee Emeritus, Cornell University | Lisa M. Skeete Tatum has been a director since 2020 and is the founder of Landit, Inc. | |
Mary K. Brainerd Board | Director | Director, Bremer Financial Corporation; Director, Securian Financial; Chair, The Nature Conservancy (MN-ND-SD); Director, The Opus Group | Mary K. Brainerd has been a director since 2017 and is the former CEO of HealthPartners. | |
Rachel Ruggeri Board | Director | EVP and CFO, Starbucks Corporation | Rachel Ruggeri has been a director since 2024 and is the CFO of Starbucks Corporation. | |
Rajeev Suri Board | Director | Chairman, Digicel Group; Director, Singtel; Director, Viasat | Rajeev Suri has been a director since 2018 and is the former CEO of Nokia and Inmarsat. | |
Ronda E. Stryker Board | Director | Vice Chair, Greenleaf Trust; Vice Chair, Spelman College Board of Trustees; Member, Harvard Medical School Board of Fellows | Ronda E. Stryker has been a director since 1984 and is the largest individual shareholder of Stryker. | |
Sherilyn S. McCoy Board | Lead Independent Director | Director, AstraZeneca; Director, Kimberly-Clark | Sherilyn S. McCoy has been a director since 2018 and became Lead Independent Director in 2022. She is the former CEO of Avon Products. |
-
Given the significant margin expansion required in the second half to meet your goal of 100 basis points operating margin growth for 2024, what specific actions are you implementing to achieve this, and how confident are you in the visibility of both gross margin improvements and SG&A leverage?
-
The Foot & Ankle market has been unexpectedly soft for two consecutive quarters; what proactive measures are you taking to address this downturn, and what strategies do you have in place if the anticipated rebound does not occur as quickly as expected?
-
Recent supply chain disruptions, particularly in flow diverters within your Neurovascular business, have impacted performance; can you detail the underlying causes, your timeline for resolution, and how these issues might influence your growth outlook in this segment?
-
Despite recognizing the potential in the tissue surgical robotics market, Stryker has not made a definitive move into this space; what are the key obstacles or strategic considerations preventing you from entering, and how do you plan to remain competitive as the market advances?
-
With recent acquisitions like Heartland in Extremities and Moly in Breast Care, how do these additions fit into your broader strategic vision, and what are your plans to effectively integrate and expand these businesses to contribute significantly to growth?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
One of the five leading global competitors in Instruments, offering surgical equipment and related technologies. | |
A competitor in both Instruments and Neurotechnology, providing a range of medical devices and technologies. | |
Competes in Instruments and Neurotechnology, offering a variety of medical and surgical products. | |
ConMed Linvatec, Inc. | A subsidiary of CONMED Corporation and a competitor in Instruments and Endoscopy, providing surgical and medical technologies. |
Karl Storz GmbH & Co. | One of the seven leading global competitors in Endoscopy, specializing in endoscopic and surgical technologies. |
Olympus Optical Co. Ltd. | A competitor in Endoscopy, known for its imaging and optical technologies. |
Competes in Endoscopy and joint replacement products, offering a range of medical devices. | |
Arthrex, Inc. | A competitor in Endoscopy, providing innovative surgical products and solutions. |
Competes in Endoscopy, offering sterilization and surgical solutions. | |
One of the five leading global competitors in Medical, providing a range of healthcare products. | |
Zoll Medical Corporation | A competitor in Medical, specializing in resuscitation and critical care technologies. |
Medline Industries | Competes in Medical, offering a wide range of healthcare supplies and solutions. |
Ferno-Washington, Inc. | A competitor in Medical, providing emergency medical and patient handling equipment. |
Terumo Corporation | One of the competitors in Neurotechnology, offering a range of medical devices and technologies. |
A competitor in Neurotechnology, specializing in neurovascular and vascular technologies. | |
DePuy Synthes | A Johnson & Johnson company and a competitor in joint replacement, trauma, extremities products, robotics, and Spine. |
A competitor in Spine, including its subsidiary NuVasive, offering a range of spinal implant and enabling technologies. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Inari Medical, Inc. | 2025 | Stryker acquired Inari Medical via a cash tender offer at $80 per share for a total fully diluted equity value of approximately $4.9 billion. The deal was executed through a merger where Inari became a wholly owned subsidiary and was subsequently delisted, strategically expanding Stryker’s Neurovascular portfolio into the high-growth peripheral vascular segment. |
SERF SAS | 2024 | Acquired on March 20, 2024 for a net cash consideration of $244 million, this acquisition boosts Stryker’s Joint Replacement business within the Orthopaedics and Spine segment by leveraging developed technology and customer relationships to strengthen its hip portfolio and global distribution footprint. |
Arlon | 2024 | Completed in July 2024, Arlon specializes in innovative soft tissue fixation products for foot, ankle, and sports medicine procedures, aligning with Stryker's strategic focus in enhancing its Orthopaedics and Spine offerings. |
MOLLI Surgical Inc. | 2024 | Completed in July 2024, the acquisition of MOLLI Surgical Inc. brings a wire‑free soft tissue localization system featuring a 3.2 mm marker and real‑time feedback into Stryker's breast cancer surgery portfolio, complementing existing technologies and improving surgical workflow. |
NICO Corporation | 2024 | Finalized in September 2024, this deal added minimally invasive tumor and intracerebral hemorrhage (ICH) solutions including BrainPath® and Myriad® products to Stryker’s neurotechnology portfolio, enhancing its capabilities for tumor resection and stroke care. |
Vertos Medical | 2024 | Acquired in 2024, Vertos Medical provides a minimally invasive solution for treating chronic lower back pain due to spinal stenosis, supporting Stryker’s strategic expansion into the interventional pain management space and driving innovation in patient care. |
care.ai | 2024 | Completed in September 2024, the acquisition of care.ai enhances Stryker’s healthcare IT and connected services, particularly in virtual nursing, thereby addressing hospital staffing challenges and complementing its digital healthcare portfolio with future software upgrade potential. |
Cerus Endovascular Limited | 2023 | Acquired in 2023 for $300 million in cash with up to $225 million in future milestone payments, Cerus Endovascular Limited’s neurovascular products for hemorrhagic stroke treatment were integrated into Stryker’s portfolio, with significant associated goodwill and developed technology valued based on a 13‑year amortization period. |
Vocera Communications, Inc. | 2022 | Completed on February 23, 2022, via a cash tender offer at $79.25 per share, this $2.97 billion deal bolstered Stryker’s Medical Division by integrating digital care coordination and communication capabilities, creating substantial goodwill and intangible assets while strengthening its Advanced Digital Healthcare offerings. |
No recent press releases or 8-K filings found for SYK.